iiCON at the heart of infectious disease research This year, a new AI robotic laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases was announced in Liverpool UK. The £20 million ($26.4 million) Liverpool Accelerate Laboratory was developed through the Infection Innovation Consortium: iiCON – an initiative dedicated… Read More
A pan-European network has been established by iiCON: the Infection Innovation Consortium to help harmonise Europe’s response to infectious disease threats. iiCON secured funding from COST (European Cooperation in Science and Technology) to establish a pan-European COST Action network with over 70 collaborators from 21 countries and international… Read More
The Infection Innovation Consortium: iiCON has launched a new agreement with the Centre of Excellence for Long-Acting Therapeutics (CELT) at the University of Liverpool that will enable iiCON partners and collaborators to access the expertise and capability at CELT. CELT is a research centre focused on the… Read More
Two new UK funding initiatives will support the development of new antimicrobials and novel technology solutions to tackle infection transmission as part of an overall focus on antimicrobial resistance (AMR). In the first of these, PACE (Pathways to Antimicrobial Clinical Efficacy) has agreed a partnership with… Read More
A major milestone has been met in the construction of a new multi-million-pound health centre in Liverpool. The new Pembroke House centre will be operated jointly by Liverpool School of Tropical Medicine and iiCON: Infection Innovation Consortium. It aims to expand Liverpool’s leading capabilities in infectious disease… Read More
